Danaher's Q2 earnings beat expectations, with adjusted EPS at $1.72 and revenue at $5.743bn.

Danaher's Q2 earnings beat expectations, with adjusted EPS at $1.72 and revenue at $5.743bn, up from $1.57 and $5.59bn respectively. The biotechnology, life sciences, and diagnostics company reported a 3.5% decline in core revenue, but CEO Rainer Blair highlighted "sustained positive momentum in our bioprocessing business and strong performance at Cepheid". Despite the revenue decline, the strong Q2 results boosted Danaher's stock price by more than 7%.